Market Place
Sourcing Support
Cumberland Pharma Reports Q3 2024 Financials & Update
07 Nov 2024 //
PR NEWSWIRE
Cumberland Pharmaceuticals Receives FDA Designations for Duchenne
06 Nov 2024 //
PR NEWSWIRE
New Study Compares Caldolor® (ibuprofen injection) to ketorolac
05 Nov 2024 //
PR NEWSWIRE
Cumberland Pharmaceuticals to Announce Q3 2024 Financial Results
31 Oct 2024 //
PR NEWSWIRE
Cumberland Pharma Reports 16% Sequential Q2 Revenue Growth
06 Aug 2024 //
PR NEWSWIRE
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS
30 Jul 2024 //
PR NEWSWIRE
Cumberland Pharmaceuticals Q1 2024 Results, Company Update
07 May 2024 //
PR NEWSWIRE
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
30 Apr 2024 //
PR NEWSWIRE
New Report Supports Use of Caldolor® as A Standard of Care Across Populations
02 Apr 2024 //
PR NEWSWIRE
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
05 Mar 2024 //
PR NEWSWIRE
Cumberland Pharmaceuticals To Announce Annual 2023 Financial Results
27 Feb 2024 //
PR NEWSWIRE
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
PR NEWSWIRE
Cumberland Pharmaceuticals To Announce Third Quarter 2023 Financial Results
31 Oct 2023 //
PR NEWSWIRE
Cumberland Reports Revenue and Earnings Growth Second Quarter 2023
08 Aug 2023 //
PR NEWSWIRE
Cumberland Pharmaceuticals To Announce Second Quarter 2023 Financial Results
01 Aug 2023 //
PR NEWSWIRE
New Publication Supports The Use of Caldolor® In Newborn Pediatric Patients
26 Jun 2023 //
PR NEWSWIRE
CUMBERLAND ANNOUNCES FDA CLEARANCE OF IND FOR DIOPATHIC PULMONARY FIBROSIS
23 May 2023 //
PR NEWSWIRE
Caldolor Now FDA Approved For Treatment Of Fever & Pain In Infants
16 May 2023 //
PR NEWSWIRE
Cumberland Pharmaceuticals Reports1Q 2023 FYR & Company Update
09 May 2023 //
PR NEWSWIRE
Cumberland Pharmaceuticals Reports 17% Revenue Growth For Full Year 2022
07 Mar 2023 //
PR NEWSWIRE
Cumberland Pharmaceuticals To Announce Annual 2022 Financial Results
28 Feb 2023 //
PR NEWSWIRE
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS
01 Nov 2022 //
PRNEWSWIRE
Cumberland Pharmaceuticals Reports 14% Revenue Growth
09 Aug 2022 //
PRNEWSWIRE
CUMBERLAND PHARMACEUTICALS REPORTS 2021 UPDATE
08 Aug 2022 //
PRNEWSWIRE
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS
02 Aug 2022 //
PRNEWSWIRE
CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS
19 Jul 2022 //
PRNEWSWIRE
Cumberland Pharmaceuticals Reports 6% Revenue Growth
10 May 2022 //
PRNEWSWIRE
Cumberland Pharma Announces Key Co-Promotion Agreement with Verity Pharma
09 May 2022 //
PRNEWSWIRE
Cumberland Pharmaceuticals To Announce First Quarter 2022 Financial Results
03 May 2022 //
PRNEWSWIRE
Tabuk And Cumberland Partner To Bring Innovative Antibiotic
31 Mar 2022 //
PRNEWSWIRE
CUMBERLAND Pharma REPORTS 2021 FINANCIAL RESULTS & COMPANY UPDATE
08 Mar 2022 //
PRNEWSWIRE
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2021 FINANCIAL RESULTS
01 Mar 2022 //
PRNEWSWIRE
CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO FROM KYOWA KIRIN NORTH AMERICA
04 Jan 2022 //
PRNEWSWIRE
Caldolor Now FDA Approved For Pre-Operative Administration
29 Nov 2021 //
PRESS RELEASE
Cumberland Reports Q3 2021 Financial Results & Company Update
09 Nov 2021 //
PRNEWSWIRE
Cumberland 2.5M Patient Doses Delivered, No Product Recalls, No FDA Issues 2020
26 Jul 2021 //
PRNEWSWIRE
Vibativ® Helps Treat Secondary Bacterial Infections In COVID-19 Patients
21 Jun 2021 //
PRNEWSWIRE
New Publication Reveals Real-World Usage of Vibativ® In Patients
26 May 2020 //
PR NEWSWIRE
Vibativ® Sustained Potency Confirmed In Two Surveillance Studies
11 May 2020 //
PHARMIWEB
Cumberland Releases Inaugural Report On Its Environmental, Social And Governanc
28 Apr 2020 //
PR NEWSWIRE
To Help Prepare for the COVID-19 Patient Surge Cumberland
07 Apr 2020 //
BUSINESSINSIDER
To Help Prepare for the COVID-19 Patient Surge Cumberland of Vaprisol®
07 Apr 2020 //
PR NEWSWIRE
